Neoadjuvant Imatinib in Locally Advanced Gastrointestinal Stromal Tumors of the Stomach: Report of Three Cases
2
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Neoadjuvant imatinib therapy used to treat locally advanced or metastatic gastrointestinal stromal tumors (GI ST) remains under active investigation. We studied three cases of locally advanced gastric GISTs treated with imatinib on a neoadjuvant basis, followed by a complete surgical resection. Three patients were diagnosed with locally advanced unresectable GIST of the stomach and were started on imatinib 400 mg/day. After the imatinib treatment, partial responses were achieved in all patients and the tumors were considered resectable. Surgical resection was done after 7, 11, and 8 months of imatinib therapy, respectively. In one case, a metastatic liver lesion was detected during the imatinib treatment using computed tomography scans, so the imatinib therapy was maintained for 11 months postoperatively. In the other two patients without distant metastasis, imatinib treatment was not restarted after surgery. Mutational analysis revealed a mutation in exon 11 of the c-kit gene in two patients, and wild-type c-kit and PDGFRA in one patient. During pathology review of all three cases, we noted several features common to imatinib treatment. There was no evidence of tumor recurrence in all three patients at respective follow-up visits of 22, 15, and 7 months. These results suggest that the neoadjuvant imatinib therapy is a potentially curative approach for selected patients with locally advanced GIST. (Cancer Res Treat. 2006;38:178-183)
Abstract
Neoadjuvant imatinib therapy used to treat locally advanced or metastatic gastrointestinal stromal tumors (GI ST) remains under active investigation. We studied three cases of locally advanced gastric GISTs treated with imatinib on a neoadjuvant basis, followed by a complete surgical resection. Three patients were diagnosed with locally advanced unresectable GIST of the stomach and were started on imatinib 400 mg/day. After the imatinib treatment, partial responses were achieved in all patients and the tumors were considered resectable. Surgical resection was done after 7, 11, and 8 months of imatinib therapy, respectively. In one case, a metastatic liver lesion was detected during the imatinib treatment using computed tomography scans, so the imatinib therapy was maintained for 11 months postoperatively. In the other two patients without distant metastasis, imatinib treatment was not restarted after surgery. Mutational analysis revealed a mutation in exon 11 of the c-kit gene in two patients, and wild-type c-kit and PDGFRA in one patient. During pathology review of all three cases, we noted several features common to imatinib treatment. There was no evidence of tumor recurrence in all three patients at respective follow-up visits of 22, 15, and 7 months. These results suggest that the neoadjuvant imatinib therapy is a potentially curative approach for selected patients with locally advanced GIST. (Cancer Res Treat. 2006;38:178-183)
참고문헌 (15)
- "Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs)", 38, pp.39~51 (2002)
- "Consensus meeting for the management of gastrointestinal stromal tumors", 16, pp.566~578 (2005)
- "Clinical management of gastrointestinal stromal tumors", 33, pp.466~477 (2002)
- "PDGFRA activating mutations in gastrointestinal stromal tumors", 299, pp.708~710 (2003)
- "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor", 21, pp.4342~4349 (2003)
- "Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors", 10, pp.3076~3081 (2004)
- "Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study", 39, pp.2006~20 (2003)
- "Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib", 364, pp.1127~1134 (2004)
- "Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors", 347, pp.472~480 (2002)
- "Imatinib and gastrointestinal stromal tumors", 4, pp.495~501 (2005)
- "Efficacy of imatinib mesylate and c-kit mutations in metastatic or unresectable GISTs", 15, pp.760~ (2004)
- "Gastrointestinal stromal tumour treated with neoadjuvant imatinib", 58, pp.779~781 (2005)
- "Outcome of advanced gastrointestinal stromal tumor (GIST) patients treated with imatinib mesylate", pp.~7 (2006)
- "Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate", 36, pp.17~24 (2006)
- "Surgical treatment of patients with initially inoperable and", or metastatic gastrointestinal stromal tumors during therapy with imatinib mesylate, 2006, pp.93(wecki z), 304~311